Tonix Pharmaceuticals to Present at the 12th Annual BIO Asia International Conference

NEW YORK, March 20, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a pharmaceutical company with clinical-stage development programs in fibromyalgia, post-traumatic stress disorder (PTSD), and episodic tension-type headache, will present at the 12^th Annual BIO Asia International Conference to be held at the Grand Hyatt in Tokyo, Japan. Seth Lederman, M.D., president and CEO of Tonix, will deliver a corporate overview on Tuesday, March 24, 2015 at 11:45 a.m. Japan Time.

The 12^th Annual BIO Asia International Conference, co-hosted by the Biotechnology Industry Organization (BIO), BioCentury, and the Japan Bioindustry Association (JBA), brings together the global biotechnology and pharmaceutical industry to explore licensing and research collaborations in the current Asia-Pacific business and policy environments.

About Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals is dedicated to the development of next-generation medicines for common yet challenging disorders of the central nervous system, characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden. Tonix's TNX-102 SL is in development as a first-line treatment for fibromyalgia and for PTSD. A Phase 2 study in PTSD is underway, and Tonix will initiate a Phase 3 trial in fibromyalgia in the second quarter of 2015. A Phase 2 trial of TNX-201 for episodic tension-type headache will also begin in the second quarter of 2015. To learn more, please visit www.tonixpharma.com.

Cautionary Note on Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our possible need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K filed with the SEC on February 27, 2015 and future periodic reports filed with the Securities and Exchange Commission. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.

CONTACT: For additional information contact:

         Tonix Pharmaceuticals Holding Corp.
         Leland Gershell
         Chief Financial Officer
         (212) 980-9155 x104
         leland.gershell@tonixpharma.com

         Martini Communications
         Amy Martini (investors)
         amartini@martinicommunications.com

         Dian Griesel Int'l.
         Susan Forman/Laura Radocaj (media)
         (212) 825-3210
         sforman@dgicomm.com
         lradocaj@dgicomm.com

Released March 20, 2015